Kilitch Drugs (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2025
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs (India) Limited held its 33rd Annual General Meeting on Friday, September 26, 2025, via video conferencing. The meeting was short, running only from 9:30 AM to 9:48 AM, with 59 members in attendance (3 from the promoter group and 56 from the public). No registered speaker shareholders participated. Seven resolutions were transacted, including adoption of the FY25 audited standalone and consolidated financial statements, re-appointment of Mr. Bhavin Mehta as a director retiring by rotation, re-appointment of Mr. Mukund Mehta as Managing Director for another 5-year term, continuation of Independent Director Mr. Vasudev Krishna Murti beyond age 75, appointment of M/s Deep Shukla & Associates as Secretarial Auditor, waiver of Performance Linked Incentive (PLI) for executive directors, and ratification of the Cost Auditor's remuneration. Detailed voting results and the Scrutinizer's Report are yet to be filed with the stock exchanges.
This is largely a routine procedural disclosure, but investors should watch for the forthcoming voting results — particularly on the special resolutions for MD re-appointment and the waiver of executive PLI — as any significant dissent could be a red flag. The brief, uneventful meeting and absence of speaker shareholders suggest no major controversy on the floor.